Why Amgen’s recent move is tied to earnings and pipeline news Amgen (AMGN) has been back on many investors’ screens after a strong third quarter, with double digit revenue growth and a wider mix of ...

Johnson & Johnson’s post-Kenvue shift boosts growth and free cash flow, with an elite balance sheet but mixed revisions.

If you want to know who really controls Amgen Inc. (NASDAQ:AMGN), then you'll have to look at the makeup of its share ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side ...

In a report released yesterday, Geoff Meacham from Citi maintained a Hold rating on Amgen, with a price target of $315.00. The company’s shares closed yesterday at $325.54.

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Amgen, with a price target of $385.00. According to TipRanks, Chen is a 3-star analyst with an average return of 1.3% ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Goldman Sachs reiterates Buy rating and $403 price target for Amgen due to strong portfolio execution and 6 key growth ...

Both stocks are strong options for dividend seekers to add to their portfolios. Let's examine closely how 2026 could unfold ...

As of Wednesday, January 07, Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 7.85%, which has investors questioning if this is right time to buy.

Energy industry stocks and oil prices are rising after the U.S. seized Venezuelan President Nicolás Maduro and his wife in a military operation on Saturday. In Wall Street trading on Monday, shares in ...